BACKGROUND: Ductal Carcinoma In Situ (DCIS) can progress to ipsilateral invasive breast cancer (IBC) but over 75% of DCIS lesions do not progress if untreated. Currently, DCIS that might progress to IBC cannot reliably be identified. Therefore, most ...
Predicting low nuclear grade DCIS before surgery can improve treatment choices and patient care, thereby reducing unnecessary treatment. Due to the high heterogeneity of DCIS and the limitations of biopsies in fully characterizing tumors, current dia...
BACKGROUND: With the development of novel anti-HER2 targeted drugs, such as ADCs, it has become increasingly important to accurately interpret HER2 expression in breast cancer. Previous studies have demonstrated high intra-observer and inter-observer...
In breast carcinoma, invasive ductal carcinoma (IDC) is the most common histopathologic subtype, and ductal carcinoma in situ (DCIS) is a precursor of IDC. These two often occur concomitantly. The immunohistochemical staining of estrogen receptor (ER...
BACKGROUND: Patients with a Breast Imaging Reporting and Data System (BI-RADS) 4 mammogram are currently recommended for biopsy. However, 70-80% of the biopsies are negative/benign. In this study, we developed a deep learning classification algorithm...
Cancer imaging : the official publication of the International Cancer Imaging Society
Apr 5, 2024
BACKGROUND: Ductal Carcinoma In Situ (DCIS) can progress to invasive breast cancer, but most DCIS lesions never will. Therefore, four clinical trials (COMET, LORIS, LORETTA, AND LORD) test whether active surveillance for women with low-risk Ductal ca...
An intraoperative diagnosis is critical for precise cancer surgery. However, traditional intraoperative assessments based on hematoxylin and eosin (H&E) histology, such as frozen section, are time-, resource-, and labor-intensive, and involve specime...
AIMS: Risk stratification of atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS), diagnosed using breast biopsy, has great clinical significance. Clinical trials are currently exploring the possibility of active surveillance for low...
OBJECTIVES: To assess the performance of an artificial intelligence (AI) algorithm in the Australian mammography screening program which routinely uses two independent readers with arbitration of discordant results.
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.